Effect of the Biofield Energy Treated Proprietary Test Formulation for Sleep Biomarkers in the Unpredictable Chronic Stress (UCS) Animal Model

Sleep biomarkers in brain such as melatonin, BDNF (Brain-derived neurotrophic factor), PGD2 (Prostaglandin D2), leptin, orexin-A, and acetylcholine were evaluated in the unpredictable chronic stress (UCS) rodent model in the presence of Consciousness Energy Healing Treated (the Trivedi Effect®) novel test formulation in male Sprague Dawley (SD) rats using ELISA assay. The test formulation was consisted of minerals (Zn, Fe, Cu, Se, Ca, Mg), vitamins (C, E, B6, B12, D3), β-carotene, ginseng, and cannabidiol isolate. The test formulation constituents were divided into two parts, one part of each ingredient was distinct as the untreated test formulation, while the other portion of the test formulation and a group of animals received Biofield Energy Healing Treatment by a renowned Biofield Energy Healer, Mr. Mahendra Kumar Trivedi. The level of melatonin in groups viz. G5 (Biofield Energy Treated Test formulation) and G7 (15-days pre-treatment of Biofield Energy Treated Test formulation) was significantly increased by 17.6% (p≤0.01) and 16%, respectively as compared with the disease control group (G2). Brain-derived neurotrophic factor (BDNF) level in brain was increased by 5.2% in G7 group as compared with the G4. Prostaglandins D2 (PGD2) level was significantly (p≤0.001) increased by 12.7%, 18.1%, 23.7%, and 30.7% in the G6, G7, G8 (15 days pre-treatment of Biofield Energy Treated Test formulation to the Biofield Energy Treatment per se rats), and G9 (untreated test formulation to the Biofield Energy Treatment per se to the rats) groups, respectively as compared with the G2. The level of leptin after Biofield Energy Treatment and with the test formulation was altered. However, orexin-A level was significantly decreased by 37.1% (p≤0.05), 32.6%, 40.5% (p≤0.05), 44.4% (p≤0.05), and 28.2% in the G5, G6, G7, G8, and G9 groups respectively, as compared with the G2. Similarly, acetylcholine (Ach) level was significantly (p≤0.001) decreased by 42.5%, 49.2%, 40.1%, 47.9%, and 45% in the G5, G6, G7, G8, and G9 groups, respectively as compared with the G2. Overall, the results showed the significant slowdown the stress-related disease progression and its complications/symptoms in the preventive in the Biofield Energy Treatment group per se and/or Biofield Energy Treated Test formulation groups (viz. G6, G7, G8, and G9) comparatively with the disease group. The Trivedi Effect® showed increased level of melatonin and decreased levels of insomnia related brain biomarkers which might be helpful to induce better sleep in human.

Download Full-text

Evaluation of Stress Biomakers (Cytokines) in Presence of Unpredictable Chronic Stress (UCS) in Sprague Dawley Rats after Treatment with the Biofield Energy Treated Novel Proprietary Test Formulation

Annals of Advanced Biomedical Sciences ◽

10.23880/aabsc-16000163 ◽

2021 ◽

Vol 4 (2) ◽

Author(s):

Snehasis Jana

Keyword(s):

Chronic Stress ◽

Preventive Treatment ◽

Alpha Tocopherol ◽

Control Group ◽

Sprague Dawley ◽

Ginseng Extract ◽

Test Formulation ◽

Per Se ◽

Energy Healing ◽

Α Level

Unpredictable chronic stress (UCS) model was used to evaluate the effect of Consciousness Energy Healing Treatment (the Trivedi Effect®) on a novel test formulation in male Sprague Dawley (SD) rats for the estimation of serum cytokines such as TNF-Alpha, IFN-Gamma, IL-6, and IL-2, along with C-reactive protein (CRP) using ELISA assay. A test formulation was formulated including minerals (calcium, copper, iron, magnesium, selenium, and zinc), vitamins (ascorbic acid, alpha tocopherol, cholecalciferol, cyanocobalamin, and pyridoxine HCl), cannabidiol isolate, Panax ginseng extract, and β-carotene. The constituents of the test formulation were divided into two parts; one part of each ingredient was defined as the untreated test formulation, while the other parts and three groups of animal received Biofield Energy Healing Treatment remotely by a renowned Biofield Energy Healer, Mr. Mahendra Kumar Trivedi. The cytokines estimation results showed that the level of IL-2 was reduced by 14.2% in Biofield Energy Treatment per se to the rats (G6) group as compared with the disease control group (G2). TNF-α level in serum was decreased by 11% in the G6 group as compared with the G2 group. IL-6 level in serum was decreased by 21.7%, 30.8%, 16.3%, 10.1%, and 13.4% in the G5, G6, G7, G8, and G9 groups, respectively as compared with the G2. However, IFN-γ level was decreased by 18.3% and 11% in the G6 and G9 groups, respectively as compared with the G4. Similarly, CRP level was significantly decreased by 25.8%, 15.2%, and 14.6% in the G5, G6, and G7 groups respectively, as compared with the G4. All-inclusive, Mr. Trivedi’s Biofield Energy Healing Treatment/Blessing per se along with other preventive treatment groups showed a significant impact on various inflammatory disorders (gout, inflammatory arthritis myositis, rheumatoid arthritis, scleroderma, etc.). Therefore, the outcomes could be slowdown the stress-related disease progression and its complications/symptoms in the preventive maintenance groups (viz. G6, G7, G8, and G9).

Download Full-text

Prevention of Aging and Improvement of Longevity and Life-Span in D-Galactose Induced Aging Rats After Treatment with the Biofield Energy Per Se and Biofield Treated Proprietary Test Formulation

Journal Of Aging Research And Healthcare ◽

10.14302/issn.2474-7785.jarh-20-3425 ◽

2020 ◽

Vol 3 (1) ◽

pp. 48-57

Author(s):

Mahendra Kumar Trivedi ◽

Alice Branton ◽

Dahryn Trivedi ◽

Snehasis Jana

Keyword(s):

Disease Control ◽

Life Span ◽

Preventive Maintenance ◽

Control Group ◽

Sprague Dawley ◽

Test Formulation ◽

Treated Sample ◽

Klotho Protein ◽

Per Se ◽

Energy Healing

The study was aimed to investigate the potential benefits of the Consciousness Energy Healing Treatment (the Trivedi Effect®) per se and Biofield Energy Healing treated novel test formulation in male Sprague Dawley rats for their antiaging activity by monitoring aging biomarkers such as brain-derived neurotrophic factor (BDNF), silent information regulator-1 (SIRT-1), and klotho protein. The test formulation was distributed into two parts. First part did not provide any Biofield Energy Treatment was denoted as the untreated sample, however the second part was received Biofield Energy Healing Treatment by a renowned Biofield Energy Healer, Mr. Mahendra Kumar Trivedi and defined as the Biofield Energy Treated sample. In this experiment, nine groups (n=10) were assigned, in which four were preventive maintenance groups. Among them, three groups of animals were also received Biofield Energy Healing Treatment per se (at day -15). BDNF was significantly increased by 25.83%, 19.35%, and 14.67% in the Biofield Energy Treated test formulation (G5), Biofield Energy Treatment per se at day -15 (G6), and Biofield Energy Treatment per se to animals plus Biofield Treated test formulation from day -15 (G8), respectively as compared to the disease control (G2) group. Moreover, expression of SIRT-1 protein was increased by 14.63% in the G5 group than the untreated test formulation (G4) group. Additionally, SIRT-1 activity was increased by 39.7%, 32.5%, 15.9%, and 136% in the G6, Biofield Energy Treated test formulation at day -15 (G7), G8, and Biofield Treatment per se (day -15) to animals plus untreated test formulation (G9) groups, respectively than the G4 group, while it was increased by 57.3% in the G9 group as compared to the G2 group. Besides, Klotho protein in kidney homogenate was significantly increased by 16.67% in the G5 group as compared to the G2 group. Altogether, the results showed a significant improvement of longevity mediators and antiaging biomarkers in the preventive maintenance groups. Therefore, results envisaged the significant slowdown of aging-related disorders and other complications in the preventive Biofield Energy Treatment group per se and/or Biofield Energy Treated Test formulation groups (viz. G6, G7, G8, and G9) comparatively with the disease control group and could be utilized against various aging-related disorders like Alzheimer's disease, hypertension, osteoporosis, cataracts, type 2 diabetes, cancer, etc. along with it could be used to extend the life-span, stress and immune-related disorders.

Download Full-text

Brain-Derived Neurotrophic Factor in Children and Adolescents with Cirrhosis Due to Biliary Atresia

Annals of Nutrition and Metabolism ◽

10.1159/000447364 ◽

2016 ◽

Vol 69 (1) ◽

pp. 1-8

Author(s):

Maria Inês A. Wilasco ◽

Carolina Uribe-Cruz ◽

Daniele Santetti ◽

Bianca Pfaffenseller ◽

Cristina T.L. Dornelles ◽

...

Keyword(s):

Nutritional Status ◽

Biliary Atresia ◽

Children And Adolescents ◽

Neurotrophic Factor ◽

Energy Homeostasis ◽

Standard Deviation Score ◽

Brain Derived Neurotrophic Factor ◽

Control Group ◽

Anthropometric Parameters ◽

Age Ratio

Background: The nutritional status in patients with cirrhosis is not so easy to assess properly. Considering the relationship between brain-derived neurotrophic factor (BDNF) and energy homeostasis, the main aim of this study was to evaluate the concentration of BDNF in children and adolescents with cirrhosis due to biliary atresia (BA) and correlate it with their nutritional status. Methods: Fifty-three children and adolescents with cirrhosis due to BA and 33 healthy controls were enrolled in this study. Nutritional status was evaluated using anthropometric parameters, and serum BDNF was measured by ELISA. Spearman coefficient was used to evaluate the correlation between variables. Results: In the cirrhosis group, 28.8% were undernourished and in the control group, 100% were well-nourished. BDNF median values for the control and cirrhosis group were 28.5 and 9.0 pg/ml respectively. BDNF and platelets were positively associated with both Standard Deviation Score (SDS) for height-for-age ratio and SDS for triceps skinfold thickness-for-age ratio. Conclusions: Considering these associations, BDNF may be an indirect biomarker of nutritional status in children and adolescents with chronic liver disease. Further studies must be conducted to clarify the role of BDNF in this population.

Download Full-text

OP0086 GENDER INFLUENCE ON CLINICAL MANIFESTATIONS, DEPRESSIVE SYMPTOMS AND BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) SERUM LEVELS IN PATIENTS AFFECTED BY FIBROMYALGIA

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2021-eular.3326 ◽

2021 ◽

Vol 80 (Suppl 1) ◽

pp. 47.2-47

Author(s):

C. Gioia ◽

B. Lucchino ◽

C. Iannuccelli ◽

G. Dolcini ◽

M. DI Franco

Keyword(s):

Depressive Symptoms ◽

Serum Level ◽

Mood Disorders ◽

Neurotrophic Factor ◽

Fibromyalgia Impact Questionnaire ◽

Clinical Manifestations ◽

Serum Levels ◽

Brain Derived Neurotrophic Factor ◽

Control Group ◽

Males And Females

Background:Fibromyalgia (FM) is a common rheumatic disease characterized by chronic widespread pain, sleep and mood disorders. A higher prevalence of FM in women compared with men is well known, although the specific differences in clinical manifestations related to gender are still poorly defined. Brain-Derived Neurotrophic Factor (BDNF) is an endogenous growth factor that gained attention for its potential as biomarker of several diseases, including FM and depression.Objectives:The aims of this study were to investigate gender-related difference among males and females affected by FM in clinical manifestations, depressive features and BDNF serum level, evaluating also the diagnostic potential of the latter.Methods:We consecutively enrolled adult patients affected by FM (ACR 2016) referring to our out-patient clinic. Each subject underwent clinical and answered to questionnaires for the severity of FM symptoms (Revised Fibromyalgia Impact Questionnaire, R-FIQ) and depressive symptoms (Beck Depression Inventory-II, BDI-II). We collected blood samples from a subgroup of patients of both sexes, matched for age, for BDNF serum level dosage through ELISA. BDNF levels were assessed also in a control group, matched for sex and age.Results:The cohort was composed by 201 FM patients (172 F, 29 M), mean age 49.13. Females showed higher values of R-FIQ total score (p=0,0005) as well the specific items of the R-FIQ for pain (p=0,013), fatigue (p=0,014), memory problems (p=0,007), tenderness to touch (p<0,0001), balance problems (p<0,0001) and sensitivity to environmental stimuli (p=0,012) when compared with males (fig. 1). There was no difference in BDI-II between males and females, but notably male patients reported a significantly higher frequency of coexisting depressive disorder (p=0,038) (fig. 2). Serum BDNF levels were evaluated in 40 FM patients and 40 healthy controls (HC) (F:M 1:1). BDNF levels were significantly lower in FM patients compared with HC (p<0,0001). Among FM patients, BDNF levels were lower in males compared with females (p<0,0001) (fig.3). BDNF did not correlate with any clinical and clinimetric parameter. BDNF showed a good diagnostic performance (AUC=0,89, CI95%=0,82-0,9630, p<0,0001) (fig. 4). At a cut-off value <6,47 ng/dl, BDNF showed a specificity of 75% and a sensibility of 92,31%,(CI 95%=79,68-97.35) for FM identification (LR=3,692).Conclusion:FM clinical manifestations are strongly dependant from gender. While females present a more severe disease and a higher burden of symptoms, mood disorders tend to be a major characteristic of males with FM. Reduced BDNF serum levels have been reported as typical of depressive disorders. Our findings of lower BDNF levels in male FM patients compared to females support this hypothesis. BDNF have potential as biomarker of the disease and should be validated in larger cohorts.References:[1]Sarzi-Puttini et al. Nature Reviews 2020[2]Colucci-D’Amato et al. Int J Molecular Sciences 2020[3]Nugraha et al. Rheumatol Int 2012[4]Schmitt et al. Ann Med 2016[5]Melchior et al. Neuroscience 2016[6]Stefani et al. Neuroscience Letters 2012Disclosure of Interests:None declared

Download Full-text

AN EXPERIMENTAL STUDY EVALUATING THE INFLUENCE OF QUERCETIN ON MONOSODIUM GLUTAMATE-INDUCED DEPRESSION IN SWISS ALBINO MALE MICE

Asian Journal of Pharmaceutical and Clinical Research ◽

10.22159/ajpcr.2019.v12i5.32986 ◽

2019 ◽

pp. 292-294

Author(s):

SRIRAM BS ◽

RAVICHANDRA V

Keyword(s):

Experimental Study ◽

Behavioral Disorders ◽

Neurotrophic Factor ◽

Monosodium Glutamate ◽

Antidepressant Activity ◽

Brain Derived Neurotrophic Factor ◽

Control Group ◽

Male Mice ◽

Significant Difference

Objective: The objective of the study was to evaluate the antidepressant activity of quercetin in monosodium glutamate (MSG) model of depressed male mice. Methods: MSG was administered (500 mg/kg) to different groups of albino male mice daily for 21 days to induce depression. The interventions (Quercetin and imipramine) were started on day 9th and continued till 21st day. On 23rd day, mice are sacrificed, hippocampus and amygdala supernatant are subjected for analysis. p<0.05 was considered as statistically significant. Results: There was a statistically significant reduction in interleukin (IL)-6 levels in animals treated with quercetin and imipramine compared to control group (p<0.001). There was also a statistically significant increase in brain-derived neurotrophic factor (BDNF) levels in quercetin with MSG groups (p<0.05) and imipramine with MSG groups (p<0.01). There was no statistically significant difference in IL-6 and BDNF levels between the groups of animals treated with quercetin (100 mg/kg) and imipramine (10 mg/kg) alone. Conclusion: Quercetin appeared to have an antidepressant activity. More extensive research is required to substantiate and elucidate the role of quercetin in behavioral disorders such as depression.

Download Full-text

Elevated levels of serum, but not salivary, brain-derived neurotrophic factor following mild traumatic brain injury in collegiate athletes post return-to-play

Journal of Concussion ◽

10.1177/2059700219894108 ◽

2019 ◽

Vol 3 ◽

pp. 205970021989410

Author(s):

Taylor R Susa ◽

Ryan D Brandt ◽

Keara J Kangas ◽

Catherine E Bammert ◽

Erich N Ottem ◽

...

Keyword(s):

Traumatic Brain Injury ◽

Brain Injury ◽

Mild Traumatic Brain Injury ◽

Neurotrophic Factor ◽

Collegiate Athletes ◽

Brain Derived Neurotrophic Factor ◽

Return To Play ◽

Control Group ◽

The Relationship ◽

Serum Bdnf

Brain-derived neurotrophic factor (BDNF) helps restore neuronal function following mild traumatic brain injury. BDNF levels can be obtained in blood serum and more recently in saliva. However, the relationship between serum and salivary BDNF is poorly understood—especially in relation to alterations in BDNF levels following mild traumatic brain injury. In this study, serum and salivary BDNF were collected from a sample of 42 collegiate student athletes. Half of the participants were recently cleared by a physician and/or an athletic trainer to return-to-play after experiencing a sports-related concussion. The other half had not experienced a concussion within the past year and were matched by age, sex, sport, and time of sample. Results suggest that incidences of depression, anxiety, and stress were all elevated in the concussion group, relative to the control participants. When controlling for stress-related negative affect, serum BDNF was elevated in the concussion group. However, there was no difference in salivary BDNF. Serum and salivary BDNF were uncorrelated across the entire sample. Yet, these measures of BDNF were correlated in the concussion group, but not the control group. In sum, serum BDNF is elevated in concussion post return-to-play; however, further research is needed to explore the utility of salivary BDNF following concussion.

Download Full-text

Interleukin-10 and brain-derived neurotrophic factor responses to the Mat Pilates training in women with multiple sclerosis

Scientia Medica ◽

10.15448/1980-6108.2018.4.31668 ◽

2018 ◽

Vol 28 (4) ◽

pp. 31668

Author(s):

Elham Eftekhari ◽

Masoud Etemadifar

Keyword(s):

Multiple Sclerosis ◽

Neurotrophic Factor ◽

Training Group ◽

Serum Levels ◽

Brain Derived Neurotrophic Factor ◽

Interleukin 10 ◽

Analysis Of Covariance ◽

Control Group ◽

P Value ◽

Before And After

AIMS: To determine the effect of Mat Pilates on serum levels of interleukin-10 and brain-derived neurotrophic factor in women with multiple sclerosis.METHODS: Thirty women with multiple sclerosis with mild to moderate disability were recruited and randomly divided into equal Pilates training and Control groups. Patients in the training group accomplished a Pilates program three times a week for eight weeks. The Control group maintained their routine lifestyle. The serum level of interleukin-10 and brain-derived neurotrophic factor were measured before and after the protocol. The differences between groups were assessed by using analysis of covariance test to compare post-tests by considering covariate pre-tests (assuming a p-value <0.05 as significant).RESULTS: There were no significant changes in interleukin-10 (13.09±5.36 ng/ml in the Pilates training group compared to 13.21±4.76 ng/ml in the Control group, p= 0.81), whereas an increase in brain-derived neurotrophic factor was observed after eight-week Pilates training (11550.14±2619.60 ng/ml in the Pilates training group compared to 9664.35±3161.66 ng/ml in the Control group, p= 0.03).CONCLUSIONS: The results suggest that the intensity and duration of this protocol was not related to significant changes in interleukin-10, but was followed by an increase in brain-derived neurotrophic factor in these patients. Based on this finding, physical activity according to the individual’s ability is recommended for patients with multiple sclerosis, in parallel with drug therapy.

Download Full-text

Resilience to Chronic Stress Is Mediated by Hippocampal Brain-Derived Neurotrophic Factor

Journal of Neuroscience ◽

10.1523/jneurosci.5725-10.2011 ◽

2011 ◽

Vol 31 (12) ◽

pp. 4475-4483 ◽

Cited By ~ 155

Author(s):

D. Taliaz ◽

A. Loya ◽

R. Gersner ◽

S. Haramati ◽

A. Chen ◽

...

Keyword(s):

Chronic Stress ◽

Neurotrophic Factor ◽

Brain Derived Neurotrophic Factor

Download Full-text

Increased oxidative stress as a mechanism for decreased BDNF levels in acute manic episodes

Brazilian Journal of Psychiatry ◽

10.1590/s1516-44462008000300011 ◽

2008 ◽

Vol 30 (3) ◽

pp. 243-245 ◽

Cited By ~ 97

Author(s):

Flávio Kapczinski ◽

Benício N Frey ◽

Ana C Andreazza ◽

Márcia Kauer-Sant'Anna ◽

Ângelo B M Cunha ◽

...

Keyword(s):

Oxidative Stress ◽

Bipolar Disorder ◽

Neurotrophic Factor ◽

Thiobarbituric Acid ◽

Brain Derived Neurotrophic Factor ◽

Oxidative Status ◽

Control Group ◽

Healthy Controls ◽

Thiobarbituric Acid Reactive Substances ◽

Low Levels

OBJECTIVE AND METHOD: There is a growing amount of data indicating that alterations in brain-derived neurotrophic factor and increased oxidative stress may play a role in the pathophysiology of bipolar disorder. In light of recent evidence demonstrating that brain-derived neurotrophic factor levels are decreased in situations of increased oxidative stress, we have examined the correlation between serum thiobarbituric acid reactive substances, a measure of lipid peroxidation, and serum brain-derived neurotrophic factor levels in bipolar disorder patients during acute mania and in healthy controls. RESULTS: Serum thiobarbituric acid reactive substances and brain-derived neurotrophic factor levels were negatively correlated in bipolar disorder patients (r = -0.56; p = 0.001), whereas no significant correlation was observed in the control group.. CONCLUSION: These results suggest that alterations in oxidative status may be mechanistically associated with abnormal low levels of brain-derived neurotrophic factor observed in individuals with bipolar disorder.

Download Full-text

The role of dendritic brain-derived neurotrophic factor transcripts on altered inhibitory circuitry in depression

10.1101/333294 ◽

2018 ◽

Author(s):

Hyunjung Oh ◽

Sean C. Piantadosi ◽

Brad R. Rocco ◽

David A. Lewis ◽

Simon C. Watkins ◽

...

Keyword(s):

Gene Expression ◽

Chronic Stress ◽

Pyramidal Cell ◽

Neurotrophic Factor ◽

Cortical Neurons ◽

Pyramidal Neurons ◽

Cell Structure ◽

Brain Derived Neurotrophic Factor ◽

Inhibitory Circuitry ◽

Synaptic Markers

ABSTRACTBackgroundA parallel downregulation of brain-derived neurotrophic factor (BDNF) and somatostatin (SST), a marker of inhibitory γ-amino-butyric acid (GABA) interneurons which target pyramidal cell dendrites, has been reported in several brain areas of subjects with major depressive disorder (MDD), and rodent genetic studies suggests they are linked and both contribute to the illness. However, the mechanism by which they contribute to the pathophysiology of the illness has remained elusive.MethodsWith qPCR, we determined the expression level of BDNF transcript variants and synaptic markers in the prefrontal cortex (PFC) of MDD patients and matched controls (n=19/group) and of C57BL/6J mice exposed to chronic stress or control conditions (n=12/group). We next suppressed BDNF transcripts with long 3’ untranslated region (L-3’-UTR) using small hairpin RNA (shRNA) and investigated changes in cell morphology, gene expression and behavior.ResultsL-3’-UTR containing BDNF mRNAs, which migrate to distal dendrites of pyramidal neurons, are selectively reduced and highly correlated with SST expression in the PFC of MDD subjects. A similar downregulation occurs in mice submitted to chronic stress. We next show that Bdnf L-3’-UTR knockdown is sufficient to induce (i) dendritic shrinkage in cortical neurons, (ii) cell-specific MDD-like gene changes (including Sst downregulation), and (iii) depressive-/anxiety-like behaviors. The translational validity of the Bdnf L-3’-UTR shRNA-treated mice was confirmed by significant cross-species correlation of changes in MDD-associated gene expression.ConclusionThese findings provide evidence for a novel MDD-related pathological mechanism linking local neurotrophic support, pyramidal cell structure, dendritic inhibition and mood regulation.

Download Full-text